文献速递淋巴瘤造血干细胞移植与细胞治疗

继发性中枢神经系统淋巴瘤:缓解适应性的巩固与挽救策略

Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort.
PubMed 文献 · Br J Haematol · 2026-06-25

该多中心回顾性队列纳入2016至2024年德国四家学术中心连续治疗的105例成人继发性中枢神经系统淋巴瘤(SCNSL)患者,分析治疗顺序、缓解动态与结局。中位无进展生存期(PFS)为7.62个月(95%CI 5.34-9.90),中位总生存期(OS)为16.62个月(95%CI 5.91-27.33)。大剂量化疗联合自体造血干细胞移植(HDT-AHSCT)巩固与OS和PFS改善相关,移植前达完全缓解者结局更优。

要点

  • HDT-AHSCT巩固与SCNSL患者OS和PFS显著改善相关。
  • HDT-AHSCT前达到完全缓解者结局更优。
  • 复发/难治SCNSL中CAR T在探索性分析中优于非移植挽救治疗。

核心结论

  • 早期缓解与HDT-AHSCT巩固是SCNSL持久疾病控制的关键决定因素。
  • CAR T治疗可能成为部分复发/难治SCNSL患者的挽救策略。
  • 研究结果为SCNSL风险适应性治疗顺序提供临床相关基准。

研究设计与样本

  • 多中心回顾性队列研究,纳入德国四家学术中心2016至2024年连续治疗的105例成人SCNSL患者。
  • 收集详细治疗顺序、缓解动态和结局数据。

主要发现

  • 中位PFS为7.62个月(95%CI 5.34-9.90),中位OS为16.62个月(95%CI 5.91-27.33)。
  • 单变量和多变量分析中,HDT-AHSCT巩固与OS和PFS显著改善相关。
  • HDT-AHSCT前达到完全缓解者结局更优。
  • 复发/难治SCNSL小样本探索性单变量分析中,CD19 CAR T较非移植挽救治疗显示更优结局:OS HR 0.28(95%CI 0.08-0.94,p=0.039),PFS HR 0.37(95%CI 0.16-0.88,p=0.025)。

临床怎么用

  • 对适合患者考虑HDT-AHSCT巩固,并争取移植前达到完全缓解。
  • 复发/难治SCNSL可评估CD19 CAR T作为挽救治疗选择。
  • 治疗决策可参考本队列PFS与OS基准进行风险适应性排序。

局限性

  • 为回顾性队列研究,样本量105例。
  • CAR T相关比较为小样本探索性单变量分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary central nervous system lymphoma (SCNSL) remains a rare but challenging manifestation of aggressive lymphomas, with limited prospective data to guide treatment decisions in the modern therapeutic era. We conducted a multicentre retrospective cohort study of 105 consecutively treated adult patients diagnosed with SCNSL between 2016 and 2024 across four German academic centres, capturing detailed treatment sequencing, response dynamics and outcome data. Median progression-free survival (PFS) was 7.62 months (95% CI 5.34-9.90), and median overall survival (OS) was 16.62 months (95% CI 5.91-27.33). Consolidation with high-dose chemotherapy and autologous haematopoietic stem cell transplantation (HDT-AHSCT) was associated with significantly improved OS and PFS in univariate and multivariate analyses. Achieving complete remission prior to HDT-AHSCT conferred with superior outcomes. In a small subset of patients with relapsed/refractory (rr) SCNSL, CD19-directed chimeric antigen receptor T-cell (CAR T) therapy showed favourable outcomes compared with non-transplant salvage therapy in exploratory univariate analysis (OS HR 0.28, 95% CI 0.08-0.94, p = 0.039; PFS HR 0.37, 95% CI 0.16-0.88, p = 0.025). In this contemporary multicentre real-world cohort, early response and consolidative HDT-AHSCT emerged as key determinants of durable disease control, while CAR T therapy may represent a salvage strategy for selected patients. These findings provide clinically relevant benchmarks to inform risk-adapted treatment sequencing in SCNSL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Eigendorff F, Görke F, Zeremski V, et al. Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort. Br J Haematol. 2026. PMID: 42351369. doi:10.1111/bjh.70633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。